A Crucial Secondary Offering At Biohaven – Insider Weekends

Biohaven Ltd (BHVN): $9.69

Market Cap: $1.29B

Enterprise Value: $1.34B

Introduction and Company Background

To readers who have been following InsideArbitrage for some time, the biotech Biohaven (BHVN) is a familiar name. The company is what I like to call a “special situations bonanza,” a company where we see multiple event-driven strategies come together at once. We’ve written about Biohaven multiple times in the past, starting with a May 2022 mid-month update describing the acquisition of the original Biohaven by Pfizer, with a spinoff of certain assets:

Only plus or premium subscribers can access this post. Subscribe today.